Immunovaccine Inc. is developing cancer vaccines using the companys DepoVaxTM vaccine technology. DepoVax is a patented formulation that displays excellent tumor control and provides a long lasting and specific effect. The way by which this vaccine exerts its effect is unclear but the translational team at Immunovaccine is determined to discover its mechanism of action and why their proprietary DepoVax technology delivers superior responses in comparison to other vaccines.
Immunovaccine Inc. is developing immune therapies for cancer using the companys DepoVaxTM vaccine technology. DepoVax is a patented formulation provides controlled and prolonged exposure of antigens and adjuvants to the immune system, resulting in a strong, specific and sustained immune response. Immunovaccines translational research team is focused on improving responses in advanced cancers by combining DepoVax based vaccines with novel immune modulators in order to improve clinical trial design.
Survivin, a member of the inhibitors of the apoptosis protein family, is involved in multiple critical pathways of cancer cell growth and survival. Because of its selective expression in cancer cells but not in normal adult tissues, survivin is an attractive target for different cancer treatments. Immunovaccine Inc. (IMV) has developed a therapeutic cancer vaccine, DPX-Survivac, targeting survivn-rich cancer cells. The description should also indicate.
IMV has developed a novel depot-based vaccine platform that can be used with a variety of antigens and adjuvants, which can exhibit rapid and enhanced immune responses following a single dosage. This project will use cell tracking via molecular MRI to explore the immune cell migration in real time in an animal model of cancer, which in turn, will affect cancer growth. The novel application of molecular MRI to track regulatory T cells and effecter cells in a tumor challenge model will yield important information on such regulatory processes.
Join a thriving innovation ecosystem. Subscribe now